Stocks Health care INMB
NASDAQ · Health careInmune Bio, Inc. (INMB)
It posted a net loss of $18.4M. In fiscal 2025 capital spending exceeded operating cash flow by $23.6M. At June 30, 2026 it held $18.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Inmune Bio, Inc.
- Net worth
- Inmune Bio, Inc. has a market value (market cap) of $31.4M at the latest share price, and shareholders' equity of $20.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $50K (+257.1% year on year), with a net loss of $45.9M.
- Cash flow
- In fiscal 2025 operations used $22.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Inmune Bio, Inc.'s next report was expected around October 29, 2026 and is not on file with the SEC yet.
What Inmune Bio, Inc. does
Inmune Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INMB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $50K | -$45.9M | -$1.86 | -$23.6M |
| 2024 | $14K | -$42.1M | -$2.11 | n/a |
| 2023 | $155K | -$30M | -$1.67 | n/a |
| 2022 | $374K | -$27.3M | -$1.52 | n/a |
| 2021 | $181K | -$30.3M | -$1.88 | n/a |
| 2020 | $11K | -$12.1M | -$1.01 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where INMB ranks in Health care
Latest SEC filings
What Inmune Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- August 6, 2026
- July 31, 2026Other event 8-K
- July 1, 2026
- June 23, 2026Other event 8-K
- June 17, 2026
- June 2, 2026Other event 8-K
- May 14, 2026Other event 8-K
- May 7, 2026
- May 5, 2026
Insider trades
What the people running Inmune Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 2, 2026 | Moss David JChief Executive Officer, Director | Exercised options | 9,014 | $12.6K |
| July 2, 2026 | Lowdell Mark WilliamChief Scientific Officer | Exercised options | 7,211 | $10.1K |
| July 2, 2026 | Juda ScottDirector | Exercised options | 14,801 | $20.7K |
Who owns INMB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Highbridge Capital Management, LLC13G, passive | 5.2% | August 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 83 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Vanguard Capital Management LLC | 706,424 | +19,409 |
| Aqr Capital Management LLC | 662,218 | +391,901 |
| BlackRock, Inc. | 311,613 | -882,499 |
| Raymond James Financial Inc | 212,995 | +9,750 |
| Geode Capital Management, LLC | 190,215 | -304,754 |
| Goldman Sachs Group Inc | 185,245 | -46,341 |
| Millennium Management LLC | 159,559 | new |
| Susquehanna International Group, Llp | 158,452 | -35,939 |
| Jane Street Group, LLC | 134,232 | +83,288 |
| UBS Group AG | 110,413 | -142,927 |
| Westside Investment Management, Inc. | 108,300 | 0 |
| Citadel Advisors LLC | 106,231 | new |
| Vanguard Fiduciary Trust Co | 104,775 | -18,409 |
| State Street Corp | 93,363 | -197,516 |
| Ieq Capital, LLC | 82,385 | +57,822 |
| Laird Norton Wetherby Trust Company, LLC | 52,000 | +2,000 |
| Focus Partners Advisor Solutions, LLC | 43,556 | +531 |
| PNC Financial Services Group, Inc. | 42,638 | +2,518 |
| Qube Research & Technologies Ltd | 40,773 | new |
| Mariner, LLC | 40,320 | +21,277 |
Insiders
3 insiders reported holding 2,899,304 shares in total, about $3.3M at the last price.
| Holder | Shares |
|---|---|
| Lowdell Mark WilliamChief Scientific Officer | 1,518,017 |
| Moss David JChief Executive Officer, Director | 1,294,883 |
| Juda ScottDirector | 86,404 |
Questions about INMB
What does Inmune Bio, Inc. do?
Inmune Bio, Inc. is a company in the Health care sector, listed on NASDAQ as INMB. Its shares trade on NASDAQ under the ticker INMB.
What is Inmune Bio, Inc.'s net worth?
Inmune Bio, Inc. has a market value (market cap) of $31.4M at the latest share price, and shareholders' equity of $20.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Inmune Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $18.4M.
When did Inmune Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 23, 2026.
When is Inmune Bio, Inc.'s next earnings report?
Inmune Bio, Inc.'s next report was expected around October 29, 2026 and is not on file with the SEC yet.
Similar companies
Compare INMB with
Follow INMB
Get an email when Inmune Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Inmune Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.